REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Companyâs NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Companyâs mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Companyâs NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Companyâs third-party licensees. Source
No articles found.
Genobank is the first privacy-preserving personal DNA Kit that guarantees consumer...
Genobank is the first privacy-preserving person...
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, de...
STAAR, which has been dedicated solely to ophth...
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the develo...
Puma Biotechnology, Inc. is a biopharmaceutical...
At Delee were fundamentally changing not only the way cancer is detected but also...
At Delee were fundamentally changing not only ...
We are a commercial-stage biotech company focused on harnessing the inherent biolo...
We are a commercial-stage biotech company focus...
Founded in 1987, Merit Medical set out to build the worldâs most customer-focuse...
Founded in 1987, Merit Medical set out to build...
IVERIC bio is a gene therapy focused company developing innovative treatments for ...
IVERIC bio is a gene therapy focused company de...
Join the National Investor Network and get the latest information with your interests in mind.